Check out today’s featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A.
Omega Systems Expands Healthcare MSP Leadership with Acquisition of PEAKE Technology Partners
Omega Systems, a leading provider of managed IT, cybersecurity, and compliance services to regulated industries, today announced the acquisition of PEAKE Technology Partners, a healthcare managed services provider specializing in compliant technology solutions for healthcare providers and practitioners across the Mid-Atlantic.
The acquisition strengthens Omega’s position as a leading MSP and MSSP for the healthcare industry, expanding its technical capabilities, regional footprint, and understanding of the IT, artificial intelligence, and regulatory compliance challenges facing medical practices, physician groups, and other healthcare organizations nationwide.
“PEAKE brings deep healthcare expertise, customer focus, and they share our core values and people-first culture,” said Omega Systems CEO Mike Fuhrman. “Together, we’re better positioned than ever to help healthcare providers and practitioners enhance care delivery with confidence – offering solutions that protect data, improve operations, and ultimately support better patient outcomes.”
Founded in 2014 and based in Bowie, Maryland, PEAKE provides comprehensive managed IT services, data security, compliance, and cloud solutions designed exclusively for healthcare organizations…
Full release here, originally announced November 5th, 2025.
Optain Health Acquires EyePACS to Expand Access to Next-Generation Retinal Imaging for Primary Care and Advance Oculomics
Optain Health, a healthcare technology company applying artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to detect eye and systemic disease earlier, today announced the acquisition of EyePACS, the U.S.’s largest and most established teleophthalmology network. The partnership unites two mission-aligned leaders to expand access to retinal screening in primary care.
For more than two decades, EyePACS has powered community-based eye-disease screening across more than 740 clinical sites, including FQHCs, county health systems, and home-health programs. The network has identified more than 140,000 individuals with severe sight-threatening disease among 1.5 million patients screened.
Optain’s technology builds on and strengthens the EyePACS community-based screening network. It brings advanced AI capability and next-generation robotic retinal imaging that enable rapid, high-quality image capture without dilation or operator expertise, making retinal imaging possible wherever patients receive care.
A shared mission to prevent blindness and improve health: After two years of close collaboration, Optain and EyePACS are joining forces around a shared mission: to prevent avoidable blindness and improve systemic health through fast, accessible, and high-quality retinal imaging…
Full release here, originally announced November 6th, 2025.
BioIVT Welcomes BeCytes: Expanding Global Access to Ethically Sourced Human Biospecimens for Research
BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the acquisition of BeCytes Biotechnologies, a Barcelona, Spain-based company specializing in the coordination of the collection, processing, and distribution of high-quality human tissues and cells for biomedical research. This marks BioIVT’s continued strategy to expand in key business units supporting NAMs and absorption, distribution, metabolism, and excretion (ADME) areas.
The addition of BeCytes strengthens BioIVT’s European footprint and expands access to ethically sourced, high-quality biospecimens—particularly primary hepatocytes—for researchers worldwide. BeCytes’ deep expertise in tissue sourcing and primary cell isolation complements BioIVT’s existing biospecimen solutions and research services, including those in New Approach Methodologies (NAMs).
“As global demand increases for NAMs and more predictive research models, access to ethically sourced tissues and cells has never been more critical,” said Richard Haigh, CEO at BioIVT. “With this acquisition, we’re expanding our reach, enhancing our portfolio, and giving scientists the high-quality specimens they need to drive innovation and accelerate medical breakthroughs.”
Founded in 2015, BeCytes has cemented itself as a trusted partner to pharmaceutical, biotech, and academic researchers seeking the coordination of human tissue procurement and cell products generation…
Full release here, originally announced November 4th, 2025.
No comments:
Post a Comment